CIT and melanoma: The reciprocal bone marrow transplantation experiment, in which H2-Aacit/cit recipients (CD45.2) of WT (CD45.1) bone marrow failed to inhibit B16F10 melanoma growth, confirmed that the presence of the cit mutation in the hematopoietic compartment confers the ability to suppress melanoma growth (Fig. 2 B).